As the medicinal use of cannabis gains further legitimacy, corporations are stepping up to provide targeted cannabinoid medicines to the public. To succeed in the long-term, these companies will need to have high-quality executives and advisers that are in touch with both cannabis patients and the underlying science.
Phytecs, a biotechnology company that researches and develops new healthcare and nutrition products, which target the body’s endocannabinoid system, has one of the strongest teams in corporate cannabis history and is poised to become a leader in this newly emerging field.
Phytecs Leadership Team & Scientific Advisory Board
The leaders of Phytecs distinguish the company from competing businesses in the industry. Most members of the leadership team and Scientific Advisory Board are highly experienced veterans of medicinal cannabis research.
Dr. Raphael Mechoulam, often known as the grandfather of cannabis research, is both Executive Director of Global Research and Chair of the Scientific Advisory Board.
Dr. Mechoulam discovered tetrahydrocannabinol (THC) in 1964, and his team discovered anandamide, the first endocannabinoid, in 1992. Dr. Mechoulam has won numerous awards for his achievements, and has spoken at many medicinal cannabis conferences. No one is more qualified to lead cannabis research endeavors, and Dr. Mechoulam’s presence alone bodes very well for the future of Phytecs.
Another notable executive is Dr. James A. Duke. He worked for the United States Department of Agriculture for 32 years, including serving as the chief of three different laboratories. Dr. Duke is also a prolific author, having written over thirty books and 400 articles. His dedication to natural plant medicines is unquestionable, and will surely guide the development of Phytecs’ products.
Tony Coelho is a former six-term United States congressman and House Majority Whip. He was also the primary author of the Americans with Disabilities Act. Coelho has a unique connection to disabled citizens, and clearly believes that medicinal cannabis could be of great therapeutic benefit. His impressive accomplishments and connections will help facilitate Phytecs’ growth.
Other members of the Advisory Team include Dr. Heather Bradshaw, Dr. Jürg Gertsch, and Dr. Andrea Hohmann, who have collectively published dozens of journal articles regarding endocannabinoid and phytocannabinoid science.
The Future Direction and Goals of Phytecs
Dr. Ethan Russo, the former Senior Medical Adviser to GW Pharmaceuticals, is now Medical Director for Phytecs. Under his leadership, he will influence the overall direction of the company. Some of the conditions Phytecs will seek cannabinoid-based solutions to include cancer, diabetes, and psychiatric disorders.
With the team Phytecs has assembled, it is very likely they will be successful in developing at least a few high-quality and effective products. At best, they may become the most powerful cannabinoid pharmaceutical presence. This would be a welcome situation compared to a traditional pharmaceutical company taking over.
Of course, there will always be a major role for small, local producers, and everyone can work together to ensure the greatest availability of cannabis medicine.